PerkinElmer Launches New R&D and Manufacturing Base in China

 

 

On July, PerkinElmer officially inaugurated its new Taicang-based R&D and manufacturing base, global procurement center, and supply chain center. Covering 12,000 square meters, the state-of-the-art facility marks a key milestone in PerkinElmer’s 47-year history in China and strengthens the company’s commitment to its “In China, For China” strategy.

 

Li Bing, President of PerkinElmer Greater China, stated, “The expanded Taicang facility will focus on high-end analytical instrument manufacturing, serving industries such as semiconductors, advanced materials, biopharma, food safety, and environmental protection. We will provide an authentic customer engagement platform.”

 

 

International Trade and Economic Cooperation Delegations Visit DIRUI

 

 

From July 1 to 7, 2025, multiple international delegations participating in trade and economic cooperation training programs—hosted by China’s Ministry of Commerce and organized by the Jilin Provincial Department of Commerce and Jilin University—visited DIRUI Industrial Co., Ltd. The visits included facility tours and in-depth exchanges, exploring new opportunities for cooperation.

 

The visiting delegations included representatives from the DPRK’s Foreign Trade Officials Training Program, the Dominican Republic’s Development Aid Program, and the Guinean Diplomatic Training Program for South-South Cooperation. Comprising officials from foreign affairs, trade, health, and international cooperation departments, the groups demonstrated a strong potential for future global collaboration.

 

 

Sinocare’s Continuous Glucose Monitoring System EU MDR Certification

 

On July 4, 2025, Sinocare Inc. (stock code: 300298) announced that its newly developed Continuous Glucose Monitoring (CGM) system has received certification under the EU Medical Devices Regulation (MDR) 2017/745. Designed for individuals aged two and above, the CGM system measures glucose levels in interstitial fluid and serves as an alternative to traditional fingertip blood glucose testing, supporting diabetes treatment decision-making.

 

 

The CGM system can be used in conjunction with smart devices running compatible apps, allowing users to manually manage their treatment decisions. The company’s second-generation CGM product, while maintaining core technologies, adopts an all-in-one structural design that enhances user convenience and comfort. The MDR certification further expands the use cases for both generations of Sinocare’s CGM products.

 

 

Thai Disease Control Delegation Visits Adicon to Explore China

 

 

On July 10, 2025, Dr. Suthat Chottanapund, Deputy Director-General of the Department of Disease Control under Thailand’s Ministry of Public Health, led a delegation of advisors to visit Adicon. The visit included a tour of Adicon’s Hangzhou laboratory, cultural exhibition hall, and strategic meetings with senior management, fostering mutual trust and laying a solid foundation for future cooperation.

 

 

During the visit, the delegation learned about Adicon’s comprehensive testing capabilities—from gene sequencing platforms to AI-based pathology diagnostics, cross-regional cold chain logistics networks, and intelligent quality control systems. Delegates highly praised Adicon’s mature, large-scale operations and robust technological strengths. In particular, Adicon’s industry-leading intelligent quality control platform and its extensive, reliable cold chain logistics system were highlighted as valuable models for improving grassroots diagnostic efficiency and ensuring accuracy and timeliness in Thailand.

 

 

Health Gene Technologies (HGT) and Biofast Biotechnology Sign Strategic Agreement to Deepen Collaboration in Genetic Disease Testing

 

 

On July 10, 2025, Ningbo HEALTH Gene Technologies Co.,Ltd. (HGT) and XBiofast Biotechnology Co.,Ltd. officially signed a strategic cooperation agreement in Ningbo. The two companies will collaborate closely in the field of genetic testing for disorders such as Fragile X Syndrome and Spinal Muscular Atrophy (SMA), among others. By integrating their technologies and resources, they aim to jointly advance the clinical application of precision medicine in genetic disease prevention and control, contributing to the “Healthy China 2030” initiative.

 

 

Mr. Ding Yu, Chairman and CEO of HGT, stated:“As a committed player in the field of genetic testing, HGT has always been driven by the mission of ‘safeguarding life and health through technology.’ This partnership with Biofast marks a significant step in expanding the clinical application scenarios of our CE platform. HGT will fully leverage its technical strengths and market resources on the CE platform to work with Biofast in developing more precise and efficient genetic testing solutions for hereditary diseases, providing strong technological support for the prevention and control of birth defects in China.”